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Sir,
As pointed out in the excellent article by Miles et al (2013),
the identification of patients benefiting most from bevacizumab
remains elusive. The activity of the gemcitabine and platinum
combination in a variety of neoplasms is well described.
In metastatic breast cancer, it has often been used as a standard
regimen in patients with triple-negative disease, despite a lack of
comparative phase 3 data, especially in anthracycline and taxane
pre-treated individuals (Perez, 2004; Heinemann et al, 2006;
Sanchez-Escribano Morcuende et al, 2007; Maisano et al, 2011).
The role of gemcitabine and carboplatin in this setting has been
highlighted by its use in the control arm in randomised trials of
PARP inhibitors (Foulkes et al, 2010; Stebbing et al, 2010;
O’Shaughnessy, 2012).
The use of bevacizumab in breast cancer has been associated
with controversy and it has been combined with a wide variety
of cytotoxics (Jones and Ellis, 2011), some combinations thought to
have more benefits than others (Miller et al, 2007; O’Shaughnessy
and Brufsky, 2008; Brufsky et al, 2011; Hamilton and Blackwell,
2011; Brufsky et al, 2012; Kesikli and Kilickap, 2012). To the best of
our knowledge, the activity and toxicity of gemcitabine, carboplatin
and bevacizumab has not been described in women with metastatic
breast cancer.
The oncology cohort at the Leaders in Oncology Care (LOC)
clinic in London includes over 11 000 patients with data
prospectively recorded for the period between May 2005 and
September 2011, as previously described (Kitchen et al, 2012).
When patients attend the clinic for treatment, their toxicities are
recorded electronically on the MOSAIQ electronic medical records
package (Elekta, Stockholm, Sweden) using the Chemotherapy
Toxicity Criteria (CTCAE3.0) scale. We identified during this time,
any patients with metastatic breast cancer regardless of histology,
who received treatment with gemcitabine, carboplatin and
bevacizumab.
Patients received bevacizumab (15mgkg 1 on day 1), gemci-
tabine (1000mg/m2 on days 1 and 8) and carboplatin (AUC 5 on
day 1) for up to eight 3 weekly cycles. A total of 14 patients
were identified who received this combination; the median
progression-free survival (PFS) measured 5.1 months (95% CI
2.2–8.0 months) with a median overall survival (OS) of 8.3 months
(95% CI 6.5–10.0 months); 71% were alive at 6 months. Their
median age was 45 years old (range 31–66 years). A total of 10
patients (71%) in the cohort had triple-negative breast cancer, with
the entire cohort being negative for HER-2. The liver, lung and
bone metastases were the commonest metastatic sites, with six
individuals (43%) having metastases at all these locations. The
median number of treatments received for metastatic disease prior
to commencing treatment with gemcitabine, carboplatin and
bevacizumab was 2 (range 0–4), with nine patients (64%) having
received either an anthracycline, taxane or both in their previous
metastatic regimens prior to receiving therapy; gemcitabine,
carboplatin and bevacizumab was first-line treatment in three
individuals (21%).
The most common grade III/IV toxicities (Table 1) were fatigue
in six patients (43%) and pain in five patients, though this latter
side effect was probably related to the cancer itself (36%). Alopecia
and bleeding were not reported. Figure 1 demonstrates the OS and
PFS curves for this single cohort.
The median number of cycles of gemcitabine, carboplatin and
bevacizumab administered was 5 (range 1–8). An objective partial
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response was observed in nine patients (64%). Interestingly, nine
patients (64%) in the cohort had shown disease progression on
their previous treatment protocols and six of these (66%) then
went on to have a response to the gemcitabine, carboplatin and
bevacizumab; one individual (7%) developed brain metastases
following commencement of gemcitabine, carboplatin and
bevacizumab.
To the best of our knowledge, this is the first-line treatment with
gemcitabine, carboplatin and bevacizumab described in metastatic
breast cancer. It is difficult to make comments on efficacy from a
single arm study, but the PFS appears to be comparable with other
regimens in late-stage disease.
Bevacizumab combined with paclitaxel has been shown to
improve PFS when compared with first-line taxane therapy alone
in individuals with HER-2-negative metastatic breast cancer
(Miller et al, 2007), although its benefits in combination with
other cytotoxics has been questioned particularly when cost-
effectiveness is considered (D’Agostino, 2011). In one study in
which bevacizumab was administered as a second-line treatment
protocol in triple-negative breast cancer, the median PFS was 6.0
months (Brufsky et al, 2012), similar numerically to the results
observed here, though any comparison between studies should be
interpreted with caution. In our cohort a further two women were
treated with gemcitabine, cisplatin and bevacizumab, and data were
similar to those observed here, but we did not include these in the
primary analysis.
In summary, gemcitabine, carboplatin and bevacizumab is a
well-tolerated regime that may provide an attractive treatment
option in patients whose disease is continuing to progress
despite ongoing interventions, who are not eligible for clinical
trials. As suggested by Miles et al (2013), plasma VEGF-A and
VEGFR-2 levels may be potential predictive biomarkers in this
patients too.
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Table 1. Grade III/IV toxicities




Dry skin 1 (7)
Nausea 1 (7)
Vomiting 1 (7)
Severe anaphylaxis 1 (7)




Hot flushes 1 (7)
Nerve pain 1 (7)
Hypertension 1 (7)


















Figure 1. Kaplan–Meier curves showing overall (OS) and progression-
free survival (PFS).
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